EACS 2011: Switching from Efavirenz to Rilpivirine Single Tablet Regimen Is Safe and Effective
- Details
- Category: HIV Treatment
- Published on Monday, 17 October 2011 00:00
- Written by Liz Highleyman
People with undetectable viral load who switched from the efavirenz/tenofovir/emtricitabine Atripla single tablet regimen to the new rilpivirine/tenofovir/emtricitabine Eviplera coformulation (marketed as Complera in the U.S.) maintained full viral suppression, researchers reported at the 13th European AIDS Conference (EACS 2011) last week in Belgrade.
EACS 2011: IL28B Gene Variant that Helps Hepatitis C Treatment May Hinder HIV Treatment
- Details
- Category: HIV Treatment
- Published on Monday, 17 October 2011 00:00
- Written by Gus Cairns
A common variant in a gene that doubles the chance of hepatitis C treatment working in people coinfected with HIV may also nearly double the risk of death in patients taking antiretroviral therapy (ART), according to a report at the 13th European AIDS Conference (EACS 2011) last week in Belgrade.
EACS 2011: Incidence of Non-AIDS Malignancies Stabilizes in D:A:D Study, but Prognosis Improves
- Details
- Category: Cancer/Malignancies
- Published on Monday, 17 October 2011 00:00
- Written by Liz Highleyman
Occurrence of non-AIDS-defining cancer has remained stable in recent years, according to an analysis of the large D:A:D observational cohort presented at the 13th European AIDS Conference (EACS 2011) last week in Belgrade. Prognosis for HIV positive people with such malignancies remains poor, but appears to have improved somewhat over time.
EACS 2011: Antiretroviral Therapy Reduces Liver Fibrosis Progression in HIV/HCV Coinfected People
- Details
- Category: Fibrosis & Cirrhosis
- Published on Monday, 17 October 2011 00:00
- Written by Liz Highleyman
Earlier initiation of antiretroviral therapy (ART) and spending more time on HIV treatment may help slow liver disease progression in HIV/HCV coinfected patients, according to an Italian study using non-invasive methods presented at the 13th European AIDS Conference (EACS 2011) last week in Belgrade.
EACS 2011: Dolutegravir Highly Effective, Twice-daily Works Better for Integrase-resistant HIV Patients
- Details
- Category: HIV Treatment
- Published on Thursday, 13 October 2011 00:00
- Written by Liz Highleyman
The novel integrase inhibitor dolutegravir is among the most potent antiretroviral agents studied to date, but treatment-experienced individuals with raltegravir resistance need to take it twice-daily in order to achieve optimal concentrations, according to findings presented at the 13th European AIDS Conference (EACS 2011) this week in Belgrade.
Web Design and Development by